• Kelyniam Global reported six-month revenue of USD 1.9 million, up 39.6% year over year.
• Operating income turned positive at USD 177,970, reversing a prior-year operating loss.
• EBITDA swung to USD 185,287 from a loss a year earlier.
• Gross profit climbed 41.5% to USD 1.54 million.
• CEO Ross Bjella cited growing demand for regenerative implants; CustomizedBone sales rose more than 50%, with first Fusion PEEK + BCP implantation completed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kelyniam Global Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608110900ACCESSWRNAPR_____1205002) on August 11, 2026, and is solely responsible for the information contained therein.